Document Detail


New guideline sets the ground rules for routine molecular testing in non-small cell lung cancer.
MedLine Citation:
PMID:  23791446     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
The guest editorial highlights the new guidelines for selecting lung cancer patients for EGFR and ALK tyrosine kinase ihibitor molecular testing.
Authors:
Nathan A Pennell; Raymond R Tubbs
Related Documents :
24272356 - Hypoxic vdac1: a potential mitochondrial marker for cancer therapy.
23720056 - Tr3 modulates platinum resistance in ovarian cancer.
24198636 - Sipuleucel-t: immunotherapy for advanced prostate cancer.
23893766 - Regulation of cellular processes by interleukin-16 in homeostasis and cancer.
20600216 - Individual differences in arsenic metabolism and lung cancer in a case-control study in...
3345886 - Colorectal cancer in patients with ulcerative colitis. a population study in central is...
Publication Detail:
Type:  Editorial    
Journal Detail:
Title:  The Journal of molecular diagnostics : JMD     Volume:  15     ISSN:  1943-7811     ISO Abbreviation:  J Mol Diagn     Publication Date:  2013 Jul 
Date Detail:
Created Date:  2013-06-24     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100893612     Medline TA:  J Mol Diagn     Country:  United States    
Other Details:
Languages:  eng     Pagination:  413-4     Citation Subset:  IM    
Copyright Information:
Copyright © 2013 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.
Affiliation:
Department of Solid Tumor Oncology, Taussig Cancer Institute, Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, Ohio.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Epidemiological analysis of maxillofacial fractures treated at a university hospital, Xinjiang, Chin...
Next Document:  The challenges of comparing a clinically validated test to other methods.